JASPER THERAPEUTICS INC (JSPR)

US4718712023 - Common Stock

22.12  +0.55 (+2.55%)

JASPER THERAPEUTICS INC

NASDAQ:JSPR (12/23/2024, 8:15:02 PM)

22.12

+0.55 (+2.55%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%22.5%
Sales Q2Q%N/A
CRS97.07
6 Month-2.56%
Overview
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Ins Owners1.27%
Inst Owners97.69%
Market Cap331.80M
Shares15.00M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts86.25
Short Float %13.88%
Short Ratio7.35
IPO11-20 2019-11-20
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

JSPR Daily chart

Company Profile

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 45 full-time employees. The company went IPO on 2019-11-20. The firm is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). The company also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The firm's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. The company is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

Company Info

JASPER THERAPEUTICS INC

2200 Bridge Pkwy Suite #102

Redwood City CALIFORNIA

P: 16505491400

CEO: Bala Venkataraman

Employees: 45

Website: https://www.jaspertherapeutics.com/

JSPR News

News Image15 days ago - Market News VideoJasper Therapeutics Breaks Below 200-Day Moving Average - Notable for JSPR
News Image21 days ago - Jasper Therapeutics, Inc.Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused...

News Imagea month ago - Market News VideoNotable Two Hundred Day Moving Average Cross - JSPR
News Imagea month ago - Jasper Therapeutics, Inc.Jasper Therapeutics to Participate at Upcoming Investor Conferences

REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused...

News Image2 months ago - Jasper Therapeutics, Inc.Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused...

News Image2 months ago - Jasper Therapeutics, Inc.Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

REDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused...

JSPR Twits

Here you can normally see the latest stock twits on JSPR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example